fumarate hydratase Antibody (J-13): sc-100743

Fumarate hydratase Antibody (J-13) is a mouse monoclonal IgG2b kappa light chain antibody that detects fumarate hydratase of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). Anti-fumarate hydratase antibody (J-13) is available in a non-conjugated form, allowing for versatile applications in various experimental settings. Fumarate hydratase (J-13) monoclonal antibody is specific to a crucial mitochondrial enzyme that plays a significant role in the Krebs cycle by catalyzing the reversible hydration of fumaric acid to produce l-malic acid. This enzymatic activity is vital for cellular respiration and energy production, highlighting the importance of fumarate hydratase in metabolic processes. Notably, germline mutations in the fumarate hydratase gene are linked to a predisposition for renal defects, including multiple cutaneous and uterine leiomyoma syndrome, as well as an increased risk of renal and smooth muscle tumors, although they do not correlate with prostate cancer. Additionally, fumarate hydratase deficiency has been associated with neurological complications, such as seizures, stemming from prenatal brain dysgenesis. Anti-fumarate hydratase antibody (J-13) detects both precursor mitochondrial and cytoplasmic mature chains, making this reagent an essential tool for researchers studying the implications of fumarate hydratase in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

fumarate hydratase Antibody (J-13) References:

1. Defects of pyruvate metabolism and the Krebs cycle.  |  De Meirleir, L. 2002. J Child Neurol. 17 Suppl 3: 3S26-33; discussion 3S33-4. PMID: 12597053
2. A role for mitochondrial enzymes in inherited neoplasia and beyond.  |  Eng, C., et al. 2003. Nat Rev Cancer. 3: 193-202. PMID: 12612654
3. Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer.  |  Bevan, S., et al. 2003. Prostate Cancer Prostatic Dis. 6: 12-4. PMID: 12664059
4. Germline fumarate hydratase mutations in families with multiple cutaneous and uterine leiomyomata.  |  Martinez-Mir, A., et al. 2003. J Invest Dermatol. 121: 741-4. PMID: 14632190
5. Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma.  |  Lindner, AK., et al. 2022. Front Oncol. 12: 906014. PMID: 35912170
6. Fumarate Hydratase Variants and Their Association With Paraganglioma/Pheochromocytoma.  |  Zavoshi, S., et al. 2023. Urology. 176: 106-114. PMID: 36773955
7. Macrophage fumarate hydratase restrains mtRNA-mediated interferon production.  |  Hooftman, A., et al. 2023. Nature. 615: 490-498. PMID: 36890227
8. Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma.  |  Zheng, L., et al. 2023. J Clin Invest. 133: PMID: 37053010
9. Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.  |  Liang, J., et al. 2023. Genome Med. 15: 31. PMID: 37131267
10. AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma.  |  Zheng, L., et al. 2023. Mod Pathol. 36: 100303. PMID: 37580017
11. Fumarate Hydratase Enhances the Therapeutic Effect of PD-1 Antibody in Colorectal Cancer by Regulating PCSK9.  |  Qin, L., et al. 2024. Cancers (Basel). 16: PMID: 38398104
12. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.  |  Chen, J., et al. 2024. Clin Cancer Res. 30: 2571-2581. PMID: 38512114

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-fumarate hydratase Antibody (J-13) has 64 citations in a variety of scientific publications.

Primary antibodies like Anti-fumarate hydratase Antibody (J-13) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

fumarate hydratase Antibody (J-13) Specifications

Alternate Product Name: fumarate hydratase

Product Clone Name: J-13

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 33-511

Epitope Target: fumarate hydratase

Epitope Species: human

Product Reactivity/Detection: precursor mitochondrial and cytoplasmic mature chains of fumarate hydratase

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 100 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 64 citations in various scientific publications

Available Conjugates/Forms for fumarate hydratase Antibody (J-13): N/A

The preferred fumarate hydratase antibody is fumarate hydratase Antibody (H-6): sc-393992.